menu

Excessive Daytime Sleepiness Treatment Market

Schedule Call

Excessive Daytime Sleepiness Treatment Market

Excessive Daytime Sleepiness Treatment Market by Treatment Type (Antidepressants, Stimulants), Distribution Channel (Hospital Pharmacy, Online Pharmacy) – Global Outlook & Forecast 2022-2030

GR - 392647 Category: Pharmaceuticals

Number of pages: 100  |  Report Format: PDF  |  Published date: March 01, 2023

Historical Years – 2020  |  Base Year – 2021  |  Forecasted Years – 2022-2030


Excessive Daytime Sleepiness Treatment Market Scope

Report Attribute

Details

Market Size Value in 2021

US$ 5.46 million

Revenue Forecast in 2030

US$ 9.14 million

CAGR

5.9%

Base Year for Estimation

2021

Forecast Period

2022-2030

Historical Year

2020

Segments Covered

Treatment Type, Distribution Channel, and Region

Regional Scope

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global excessive daytime sleepiness treatment market was valued at US$ 5.46 million in 2021 and is expected to register a revenue CAGR of 5.9% to reach US$ 9.14 million by 2030.

Excessive Daytime Sleepiness Treatment Market Fundamentals

Excessive daytime sleepiness (EDS) is characterized by an overwhelming feeling of tiredness and the inability to stay awake during the day, even after sufficient sleep at night. EDS can significantly impact the quality of life, leading to decreased productivity, impaired cognitive function, and increased risk of accidents and injuries. EDS can be caused by various factors, including sleep disorders, such as sleep apnea and narcolepsy, as well as lifestyle factors, such as poor sleep habits and chronic stress.

Diagnosing EDS typically involves a thorough evaluation of a person’s sleep history and habits and physical and neurological exams. Treatment options for EDS vary depending on the underlying cause. However, they may include medications, lifestyle modifications, and behavioral therapies. Some medications used to treat EDS include stimulants, such as modafinil and armodafinil, antidepressants, and sodium oxybate. Lifestyle modifications that may help reduce symptoms of EDS include maintaining a regular sleep schedule, avoiding caffeine and alcohol, and engaging in regular exercise and relaxation techniques, such as yoga and meditation. Behavioral therapies, such as cognitive-behavioral therapy for insomnia (CBT-I), can also effectively manage EDS by addressing underlying psychological factors contributing to sleep disturbances.

[6785675]

Excessive Daytime Sleepiness Treatment Market Dynamics

The increasing prevalence of sleep disorders, such as sleep apnea, narcolepsy, restless leg syndrome, and insomnia, is the key driver of the excessive daytime sleepiness treatment market. For instance, according to the American Academy of Sleep Medicine factsheet of July 2022, while insomnia affects one in every 2,000 individuals, it is frequently undetected or misdiagnosed, leading to poor sleep quality and a lower quality of life. The development of new and effective pharmacological treatments, such as wake-promoting agents and stimulants, is also augmenting the global excessive daytime sleepiness treatment market. These treatments help to alleviate symptoms of EDS and improve the quality of life for patients. Moreover, greater awareness and diagnosis of sleep disorders and EDS also fuel the global excessive daytime sleepiness treatment market. As more people become aware of the importance of sleep and its impact on overall health, there is a greater demand for treatment options for sleep disorders and EDS.

However, the side effects of sleep disorder drugs and the limited availability of treatments are the major restraints impeding the overall EDS treatment market revenue growth. 

Excessive Daytime Sleepiness Treatment Market Ecosystem

The global excessive daytime sleepiness treatment market is analyzed from three perspectives: treatment type, distribution channel, and region.

Excessive Daytime Sleepiness Treatment Market by Treatment Type

[657857]

Based on the treatment type, the global excessive daytime sleepiness treatment market is segmented into antidepressants, stimulants, sodium oxybate, and others.

The sodium oxybate segment dominated the market with the principal revenue share in 2021, as it is an important drug for treating EDS. Sodium oxybate is a medication used in the treatment of EDS associated with narcolepsy. It is a central nervous system (CNS) depressant that increases slow-wave sleep and improves nighttime sleep quality, thereby reducing daytime sleepiness. Sodium oxybate is usually taken in two doses at night. The second dose is taken 2.5 to 4 hours after the first dose. Ongoing research is also being conducted to evaluate sodium oxybate’s efficacy and safety. These factors are contributing to significant revenue growth in the sodium oxybate segment.

Excessive Daytime Sleepiness Treatment Market by Distribution Channel 

Based on the distribution channel, the global excessive daytime sleepiness treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

The hospital pharmacies segment dominated the market with the highest revenue share in 2021, owing to the large footfall of patients in hospitals. Hospital pharmacies are often responsible for preparing and dispensing complex medications, such as sodium oxybate, used to treat EDS. Hospital pharmacies may also play a role in educating patients about using EDS medications and monitoring their treatment progress. They may work with other healthcare professionals, such as sleep specialists and neurologists, to develop comprehensive treatment plans for patients with EDS. In addition, hospital pharmacies may be involved in managing side effects associated with EDS medications. For instance, they may provide medications to help manage nausea or other symptoms that can occur as a result of treatment. These factors contribute to the hospital pharmacy segment revenue growth.

Excessive Daytime Sleepiness Treatment Market by Region

Geographically, the global excessive daytime sleepiness treatment market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World.

North America dominated the global excessive daytime sleepiness treatment market with the largest revenue share in 2021, attributed to increasing research and development activities, rising healthcare expenditure, and the presence of major key players. Additionally, the rise in the participation of regional companies in partnerships, mergers, and acquisitions activities is also helping the development of the regional market. For instance, in May 2022, Axsome Therapeutics, Inc., a biopharmaceutical company researching innovative therapeutics for the treatment of CNS diseases, announced the completion of its purchase of Sunosi (solriamfetol) from Jazz Pharmaceuticals in the United States. Sunosi is a dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) that has been shown to enhance alertness in adult patients with narcolepsy or obstructive sleep apnea (OSA). Sunosi showed great effectiveness in both subjective and objective markers of drowsiness in individuals with narcolepsy and OSA in multiple clinical studies.

Excessive Daytime Sleepiness Treatment Market Competitive Landscape

The prominent players operating in the global excessive daytime sleepiness treatment market are:

Excessive Daytime Sleepiness Treatment Market Strategic Developments

  • In February 2023, Pharmanovia announced the expansion of its neurology portfolio via a new licensing agreement with Axsome Therapeutics, Inc. Sunosi (solriamfetol), a first-in-class drug used to increase alertness and reduce EDS in individuals with narcolepsy or obstructive sleep apnoea (OSA), was expected to be marketed exclusively by Pharmanovia in Europe and the Middle East and North Africa (MENA). The agreement also covered all existing European territories and any future regional launches.
  • In November 2022, Harmony Biosciences Holdings, Inc. announced preliminary topline results from its Phase 2 proof-of-concept study in patients suffering from Prader-Willi syndrome, indicating a positive signal of improvement in the primary outcome related to EDS. The Phase 2 clinical trial was a randomized, double-blind, placebo-controlled research to evaluate pitolisant’s safety and effectiveness in PWS patients.

Frequently Asked Questions About This Report

The global excessive daytime sleepiness treatment market is expected to reach US$ 9.14 million by 2030.

The excessive daytime sleepiness treatment market is expected to register a revenue CAGR of 5.9% during the forecast period from 2022 to 2030.

A rise in awareness and diagnosis rates of sleep disorders, increase in the prevalence of sleep disorders, and the development of new and effective pharmacological treatments are driving the revenue growth of the global excessive daytime sleepiness treatment market.

The side effects of sleep disorder drugs and the limited availability of treatment are restricting the global market revenue growth to its full potential.

Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Fisher & Paykel Healthcare Limited, and Drive DeVilbiss Healthcare LLC are among the top market players.

Table of Content

  1. INTRODUCTION
    1. Market Ecosystem
    2. Timeline Under Consideration
      1. Historical Years – 2020
      2. Base Year – 2021
      3. Forecast Years – 2022 to 2030
    3. Currency Used in the Report
  2. RESEARCH METHODOLOGY
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
    4. Market Estimation Approach
      1. Bottom Up
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions
  3. PREMIUM INSIGHTS
    1. Current Market Trend (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2021) 
  4. MARKET DYNAMICS
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
  5. GLOBAL EXCESSIVE DAYTIME SLEEPINESS TREATMENT MARKET- ANALYSIS & FORECAST, BY TREATMENT TYPE
    1. Antidepressants
    2. Stimulants
    3. Sodium Oxybate
    4. Others
  6. GLOBAL EXCESSIVE DAYTIME SLEEPINESS TREATMENT MARKET- ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL
    1. Hospitals Pharmacies
    2. Retail Pharmacies
    3. Online Pharmacies
  7. GLOBAL EXCESSIVE DAYTIME SLEEPINESS TREATMENT MARKET- ANALYSIS & FORECAST, BY REGION
    1. North America Excessive Daytime Sleepiness Treatment Market
      1. North America Excessive Daytime Sleepiness Treatment Market, by Treatment Type
      2. North America Excessive Daytime Sleepiness Treatment Market, by Distribution Channel
      3. North America Excessive Daytime Sleepiness Treatment Market, by Country
        1. U.S.
          1. U.S. Excessive Daytime Sleepiness Treatment Market, by Treatment Type
          2. U.S. Excessive Daytime Sleepiness Treatment Market, by Distribution Channel
        2. Canada
          1. Canada Excessive Daytime Sleepiness Treatment Market, by Treatment Type
          2. Canada Excessive Daytime Sleepiness Treatment Market, by Distribution Channel
    2. Europe Excessive Daytime Sleepiness Treatment Market
      1. Europe Excessive Daytime Sleepiness Treatment Market, by Treatment Type
      2. Europe Excessive Daytime Sleepiness Treatment Market, by Distribution Channel
      3. Europe Excessive Daytime Sleepiness Treatment Market, by Country/Region
        1. Germany
          1. Germany Excessive Daytime Sleepiness Treatment Market, by Treatment Type
          2. Germany Excessive Daytime Sleepiness Treatment Market, by Distribution Channel
        2. U.K.
          1. U.K. Excessive Daytime Sleepiness Treatment Market, by Treatment Type
          2. U.K. Excessive Daytime Sleepiness Treatment Market, by Distribution Channel
        3. France
          1. France Excessive Daytime Sleepiness Treatment Market, by Treatment Type
          2. France Excessive Daytime Sleepiness Treatment Market, by Distribution Channel
        4. Spain
          1. Spain Excessive Daytime Sleepiness Treatment Market, by Treatment Type
          2. Spain Excessive Daytime Sleepiness Treatment Market, by Distribution Channel
        5. Italy
          1. Italy Excessive Daytime Sleepiness Treatment Market, by Treatment Type
          2. Italy Excessive Daytime Sleepiness Treatment Market, by Distribution Channel
        6. Rest of Europe 
          1. Rest of Europe Excessive Daytime Sleepiness Treatment Market, by Treatment Type
          2. Rest of Europe Excessive Daytime Sleepiness Treatment Market, by Distribution Channel
    3. Asia Pacific Excessive Daytime Sleepiness Treatment Market
      1. Asia Pacific Excessive Daytime Sleepiness Treatment Market, by Treatment Type
      2. Asia Pacific Excessive Daytime Sleepiness Treatment Market, by Distribution Channel
      3. Asia Pacific Excessive Daytime Sleepiness Treatment Market, by Country/Region
        1. China
          1. China Excessive Daytime Sleepiness Treatment Market, by Treatment Type
          2. China Excessive Daytime Sleepiness Treatment Market, by Distribution Channel
        2. Japan
          1. Japan Excessive Daytime Sleepiness Treatment Market, by Treatment Type
          2. Japan Excessive Daytime Sleepiness Treatment Market, by Distribution Channel
        3. India
          1. India Excessive Daytime Sleepiness Treatment Market, by Treatment Type
          2. India Excessive Daytime Sleepiness Treatment Market, by Distribution Channel
        4. South Korea
          1. South Korea Excessive Daytime Sleepiness Treatment Market, by Treatment Type
          2. South Korea Excessive Daytime Sleepiness Treatment Market, by Distribution Channel
        5. Australia
          1. Australia Excessive Daytime Sleepiness Treatment Market, by Treatment Type
          2. Australia Excessive Daytime Sleepiness Treatment Market, by Distribution Channel
        6. Rest of Asia Pacific
          1. Rest of Asia Pacific Excessive Daytime Sleepiness Treatment Market, by Treatment Type
          2. Rest of Asia Pacific Excessive Daytime Sleepiness Treatment Market, by Distribution Channel
    4. Rest of the World Excessive Daytime Sleepiness Treatment Market
      1. Rest of the World Excessive Daytime Sleepiness Treatment Market, by Treatment Type
      2. Rest of the World Excessive Daytime Sleepiness Treatment Market, by Distribution Channel
      3. Rest of the World Excessive Daytime Sleepiness Treatment Market, by Region
        1. Rest of the World Excessive Daytime Sleepiness Treatment Market, by Treatment Type
        2. Rest of the World Excessive Daytime Sleepiness Treatment Market, by Distribution Channel
        3. Latin America
          1. Latin America Excessive Daytime Sleepiness Treatment Market, by Treatment Type
          2. Latin America Excessive Daytime Sleepiness Treatment Market, by Distribution Channel
        4. Middle East & Africa
          1. Middle East & Africa Excessive Daytime Sleepiness Treatment Market, by Treatment Type
          2. Middle East & Africa Excessive Daytime Sleepiness Treatment Market, by Distribution Channel
  8. COMPANY PROFILES         
    1. Takeda Pharmaceutical Company Limited
      1. Business Snapshot
      2. Products Offered
      3. Financial Details*
      4. Strategic Development
    2. Teva Pharmaceutical Industries Ltd.
    3. Avadel Pharmaceuticals plc.
    4. GlaxoSmithKline plc, 
    5. Pfizer Inc.
    6. Axsome Therapeutics, Inc
    7. Suven Life Sciences
    8. NLS Pharma Ltd.
    9. Jazz Pharmaceuticals
    10. Bioprojet Pharma
    11. Fisher & Paykel Healthcare Limited
    12. Drive DeVilbiss Healthcare LLC
    13. Merck & Co. Inc.

*Insights on financial performance are subject to availability of information in the public domain

 

List of Tables

 

  1. Global Excessive Daytime Sleepiness Treatment Market, By Treatment Type, 2020-2030 (US$ Million)
  2. Global Excessive Daytime Sleepiness Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  3. Global Excessive Daytime Sleepiness Treatment Market, By Region, 2020-2030 (US$ Million) 
  4. North America Excessive Daytime Sleepiness Treatment Market, By Treatment Type, 2020-2030 (US$ Million) 
  5. North America Excessive Daytime Sleepiness Treatment Market, By Distribution Channel, 2020–2030 (US$ Million)
  6. North America Excessive Daytime Sleepiness Treatment Market, By Country, 2020-2030 (US$ Million) 
  7. U.S. Excessive Daytime Sleepiness Treatment Market, By Treatment Type, 2020-2030 (US$ Million) 
  8. U.S. Excessive Daytime Sleepiness Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  9. Canada Excessive Daytime Sleepiness Treatment Market, By Treatment Type, 2020-2030 (US$ Million) 
  10. Canada Excessive Daytime Sleepiness Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  11. Europe Excessive Daytime Sleepiness Treatment Market, By Treatment Type, 2020-2030 (US$ Million) 
  12. Europe Excessive Daytime Sleepiness Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  13. Europe Excessive Daytime Sleepiness Treatment Market, By Country/ Region, 2020-2030 (US$ Million) 
  14. Germany Excessive Daytime Sleepiness Treatment Market, By Treatment Type, 2020-2030 (US$ Million) 
  15. Germany Excessive Daytime Sleepiness Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  16. U.K. Excessive Daytime Sleepiness Treatment Market, By Treatment Type, 2020-2030 (US$ Million) 
  17. U.K. Excessive Daytime Sleepiness Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  18. France Excessive Daytime Sleepiness Treatment Market, By Treatment Type, 2020-2030 (US$ Million) 
  19. France Excessive Daytime Sleepiness Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  20. Italy Excessive Daytime Sleepiness Treatment Market, By Treatment Type, 2020-2030 (US$ Million) 
  21. Italy Excessive Daytime Sleepiness Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  22. Spain Excessive Daytime Sleepiness Treatment Market, By Treatment Type, 2020-2030 (US$ Million) 
  23. Spain Excessive Daytime Sleepiness Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  24. Rest of Europe Excessive Daytime Sleepiness Treatment Market, By Treatment Type, 2020-2030 (US$ Million)
  25. Rest of Europe Excessive Daytime Sleepiness Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  26. Asia Pacific Excessive Daytime Sleepiness Treatment Market, By Treatment Type, 2020-2030 (US$ Million) 
  27. Asia Pacific Excessive Daytime Sleepiness Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  28. Asia Pacific Excessive Daytime Sleepiness Treatment Market, By Country/ Region, 2020-2030 (US$ Million) 
  29. China Excessive Daytime Sleepiness Treatment Market, By Treatment Type, 2020-2030 (US$ Million) 
  30. China Excessive Daytime Sleepiness Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  31. Japan Excessive Daytime Sleepiness Treatment Market, By Treatment Type, 2020-2030 (US$ Million) 
  32. Japan Excessive Daytime Sleepiness Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  33. India Excessive Daytime Sleepiness Treatment Market, By Treatment Type, 2020-2030 (US$ Million) 
  34. India Excessive Daytime Sleepiness Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  35. South Korea Excessive Daytime Sleepiness Treatment Market, By Treatment Type, 2020-2030 (US$ Million) 
  36. South Korea Excessive Daytime Sleepiness Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  37. Australia Excessive Daytime Sleepiness Treatment Market, By Treatment Type, 2020-2030 (US$ Million) 
  38. Australia Excessive Daytime Sleepiness Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  39. Rest of Asia Pacific Excessive Daytime Sleepiness Treatment Market, By Treatment Type, 2020-2030 (US$ Million)
  40. Rest of Asia Pacific Excessive Daytime Sleepiness Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  41. Rest of the World Excessive Daytime Sleepiness Treatment Market, By Treatment Type, 2020-2030 (US$ Million)
  42. Rest of the World Excessive Daytime Sleepiness Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  43. Rest of the World Excessive Daytime Sleepiness Treatment Market, By Region, 2020-2030 (US$ Million) 
  44. Latin America Excessive Daytime Sleepiness Treatment Market, By Treatment Type, 2020-2030 (US$ Million) 
  45. Latin America Excessive Daytime Sleepiness Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 
  46. Middle East and Africa Excessive Daytime Sleepiness Treatment Market, By Treatment Type, 2020-2030 (US$ Million)
  47. Middle East and Africa Excessive Daytime Sleepiness Treatment Market, By Distribution Channel, 2020–2030 (US$ Million) 

List of Figures

 

  1. Excessive Daytime Sleepiness Treatment Market Ecosystem  
  2. Snapshot of Global Excessive Daytime Sleepiness Treatment Market, 2020-2030 
  3. Snapshot of Global Excessive Daytime Sleepiness Treatment Market, By Region, 2020-2030 
  4. Global Excessive Daytime Sleepiness Treatment Market: COVID-19 Pandemic Impact Assessment 
  5. Global Excessive Daytime Sleepiness Treatment Market: Key Players & Competitive Positioning (2021) 
  6. Excessive Daytime Sleepiness Treatment: Market Dynamics 
  7. Global Excessive Daytime Sleepiness Treatment Market for Antidepressants, 2020-2030 (US$ Million) 
  8. Global Excessive Daytime Sleepiness Treatment Market for Stimulants, 2020-2030 (US$ Million) 
  9. Global Excessive Daytime Sleepiness Treatment Market for Sodium Oxybate, 2020-2030 (US$ Million) 
  10. Global Excessive Daytime Sleepiness Treatment Market for Other Treatments, 2020-2030 (US$ Million) 
  11. Global Excessive Daytime Sleepiness Treatment Market for Hospital Pharmacies, 2020-2030 (US$ Million) 
  12. Global Excessive Daytime Sleepiness Treatment Market for Retail Pharmacies, 2020-2030 (US$ Million) 
  13. Global Excessive Daytime Sleepiness Treatment Market for Online Pharmacies, 2020-2030 (US$ Million) 
  14. North America Excessive Daytime Sleepiness Treatment Market, 2020-2030 (US$ Million) 
  15. U.S. Excessive Daytime Sleepiness Treatment Market, 2020-2030 (US$ Million) 
  16. Canada Excessive Daytime Sleepiness Treatment Market, 2020-2030 (US$ Million) 
  17. Europe Excessive Daytime Sleepiness Treatment Market, 2020-2030 (US$ Million) 
  18. Germany Excessive Daytime Sleepiness Treatment Market, 2020-2030 (US$ Million) 
  19. U.K. Excessive Daytime Sleepiness Treatment Market, 2020-2030 (US$ Million) 
  20. France Excessive Daytime Sleepiness Treatment Market, 2020-2030 (US$ Million) 
  21. Italy Excessive Daytime Sleepiness Treatment Market, 2020-2030 (US$ Million) 
  22. Spain Excessive Daytime Sleepiness Treatment Market, 2020-2030 (US$ Million) 
  23. Rest of Europe Excessive Daytime Sleepiness Treatment Market, 2020-2030 (US$ Million) 
  24. Asia Pacific Excessive Daytime Sleepiness Treatment Market, 2020-2030 (US$ Million) 
  25. China Excessive Daytime Sleepiness Treatment Market, 2020-2030 (US$ Million) 
  26. Japan Excessive Daytime Sleepiness Treatment Market, 2020-2030 (US$ Million) 
  27. India Excessive Daytime Sleepiness Treatment Market, 2020-2030 (US$ Million) 
  28. South Korea Excessive Daytime Sleepiness Treatment Market, 2020-2030 (US$ Million) 
  29. Australia Excessive Daytime Sleepiness Treatment Market, 2020-2030 (US$ Million) 
  30. Rest of Asia Pacific Excessive Daytime Sleepiness Treatment Market, 2020-2030 (US$ Million) 
  31. Rest of the World Excessive Daytime Sleepiness Treatment Market, 2020-2030 (US$ Million)
  32. Latin America Excessive Daytime Sleepiness Treatment Market, 2020-2030 (US$ Million) 
  33. Middle East & Africa Excessive Daytime Sleepiness Treatment Market, 2020-2030 (US$ Million) 
  34. Takeda Pharmaceutical Company Limited Revenue from 2018-2021 (US$ Million)
  35. Teva Pharmaceutical Industries Ltd. Revenue from 2018-2021 (US$ Million)
  36. Avadel Pharmaceuticals plc Revenue from 2018-2021 (US$ Million)
  37. GlaxoSmithKline plc Revenue from 2018-2021 (US$ Million)
  38. Pfizer Inc. Revenue from 2018-2021 (US$ Million)
  39. Axsome Therapeutics, Inc. Revenue from 2018-2021 (US$ Million)
  40. Suven Life Sciences Revenue from 2018-2021 (US$ Million)
  41. NLS Pharma Ltd. Revenue from 2018-2021 (US$ Million)
  42. Jazz Pharmaceuticals Revenue from 2018-2021 (US$ Million)
  43. Bioprojet Pharma Revenue from 2018-2021 (US$ Million)
  44. Fisher & Paykel Healthcare Limited Revenue from 2018-2021 (US$ Million)
  45. Drive DeVilbiss Healthcare LLC Revenue from 2018-2021 (US$ Million)
  46. Merck & Co. Inc. Revenue from 2018-2021 (US$ Million)

Single User License
Single User License
Multi User License
Enterprise User License
$4,750.00
Provides access to one user only and should not be shared with other employees within the organization.
Provides access to up to five users within the department or an organization.
Provides access to all the employees in the organization. The report can also be shared with subsidiaries, sister concerns and group entities.
Grants user/users’ access to quantitative data only, which includes but is not restricted to numeric data, tables, and charts as defined by Growth+ Reports.
  • What are the significant driving and restraining factors for the Excessive Daytime Sleepiness Treatment Market?
  • Who are the leading companies in the market?
  • Where can you find the updates on recent developments by market players?
  • When is the right time to get discounts on complete market reports?
  • Why to invest in the Excessive Daytime Sleepiness Treatment Market?
  • How to improve your organizational performance?
  • How to shift customers towards your brand?

Recommended Reports